PDGFRA and PDGFRB were targeted by multiple drugs, and imatinib, a BCR-ABL inhibitor [13], was identified to target both PDGFRA and PDGFRB in S:E fusion-positive prostate cancer. The gene discussed is ABL1; the disease is prostate cancer.